WO2001098266A3 - N-and o-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating cns disorders therewith - Google Patents

N-and o-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating cns disorders therewith Download PDF

Info

Publication number
WO2001098266A3
WO2001098266A3 PCT/US2001/040964 US0140964W WO0198266A3 WO 2001098266 A3 WO2001098266 A3 WO 2001098266A3 US 0140964 W US0140964 W US 0140964W WO 0198266 A3 WO0198266 A3 WO 0198266A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
cns disorders
diphenylmethoxy
phenyl
ethyl
Prior art date
Application number
PCT/US2001/040964
Other languages
French (fr)
Other versions
WO2001098266A2 (en
Inventor
Aloke K Dutta
Original Assignee
Univ Wayne State
Aloke K Dutta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wayne State, Aloke K Dutta filed Critical Univ Wayne State
Priority to AU2001275537A priority Critical patent/AU2001275537A1/en
Priority to US10/311,796 priority patent/US6995268B2/en
Publication of WO2001098266A2 publication Critical patent/WO2001098266A2/en
Publication of WO2001098266A3 publication Critical patent/WO2001098266A3/en
Priority to US11/007,484 priority patent/US7595331B2/en
Priority to US12/018,172 priority patent/US8211916B2/en
Priority to US12/568,503 priority patent/US20100016600A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms

Abstract

N- and O-substituted 4[2-diaromaticmethoxy and methylamino)alkyl]piperidines exhibit high CNS activity with respect to the dopamine transporter (DAT) and serotonin transporter (SERT). Preferred compounds exhibit highly differential behavior as between the DAT and SERT and between the DAT and the norepinephrine transporter (NET). The compounds have utility in treating CNS disorders, including but not limited to ***e addiction, depression, and Parkinson's disease.
PCT/US2001/040964 2000-06-20 2001-06-14 N-and o-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating cns disorders therewith WO2001098266A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001275537A AU2001275537A1 (en) 2000-06-20 2001-06-14 N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith
US10/311,796 US6995268B2 (en) 2000-06-20 2001-06-14 N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating CNS disorders therewith
US11/007,484 US7595331B2 (en) 2000-06-20 2004-12-08 N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith
US12/018,172 US8211916B2 (en) 2000-06-20 2008-01-22 N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith
US12/568,503 US20100016600A1 (en) 2000-06-20 2009-09-28 N- and O-Substituted 4-[2-(Diphenylmethoxy)-Ethyl]-1-[(Phenyl)Methyl]Piperdine Analogs and Methods of Treating CNS Disorders Therewith

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21292100P 2000-06-20 2000-06-20
US60/212,921 2000-06-20

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/311,796 Continuation US6995268B2 (en) 2000-06-20 2001-06-14 N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating CNS disorders therewith
US10311796 A-371-Of-International 2001-06-14
US11/007,484 Continuation US7595331B2 (en) 2000-06-20 2004-12-08 N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith

Publications (2)

Publication Number Publication Date
WO2001098266A2 WO2001098266A2 (en) 2001-12-27
WO2001098266A3 true WO2001098266A3 (en) 2002-04-04

Family

ID=22792949

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/040964 WO2001098266A2 (en) 2000-06-20 2001-06-14 N-and o-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating cns disorders therewith

Country Status (3)

Country Link
US (3) US6995268B2 (en)
AU (1) AU2001275537A1 (en)
WO (1) WO2001098266A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062301A2 (en) 2000-02-22 2001-08-30 Biostream, Inc. Imaging agents for diagnosis of parkinson's disease
WO2001098266A2 (en) * 2000-06-20 2001-12-27 Wayne State University N-and o-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating cns disorders therewith
US8211916B2 (en) * 2000-06-20 2012-07-03 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith
US20060122263A1 (en) * 2003-03-28 2006-06-08 Dutta Aloke K Tri-substituted 2-benzhydryl-5-benzlamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives
WO2005032479A2 (en) 2003-10-01 2005-04-14 Unviversity Of Florida Research Foundation, Inc. Compositions and methods for selective inhibition of nicotine acetylcholine receptors
EP1734948B1 (en) 2004-04-16 2014-06-11 Wayne State University Tri-substitued 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives
JP5142529B2 (en) 2004-09-30 2013-02-13 イビデン株式会社 Honeycomb structure
WO2006057344A1 (en) * 2004-11-26 2006-06-01 Ibiden Co., Ltd. Honeycomb structure
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
TW200815425A (en) * 2006-06-08 2008-04-01 Speedel Experimenta Ag 2,5-disubstituted piperidines
JP5583592B2 (en) * 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション IDO inhibitor
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP3233799B1 (en) * 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5300499A (en) * 1992-09-02 1994-04-05 Allergan, Inc. 5-substituted 3-thiophene sulfonamides as antiglaucoma agents
US5344835A (en) * 1990-01-06 1994-09-06 Pfizer Inc. Piperidine and pyrrolidine derivatives
WO1999025686A1 (en) * 1997-11-18 1999-05-27 Teijin Limited Cyclic amine derivatives and their use as drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598750B2 (en) 1985-09-27 1990-07-05 Mitsubishi Chemical Corporation Phenylalanine derivative and proteinase inhibitor
DK0417698T3 (en) 1989-09-12 1996-07-22 Hoechst Ag Amino acid derivatives with pure inhibitory properties, process for their preparation, agents thereof and their use
JPH09249566A (en) 1996-03-19 1997-09-22 Takeda Chem Ind Ltd Piperidine-containing chemokine receptor antagonist
EP0991753A4 (en) 1997-05-08 2001-07-11 Smithkline Beecham Corp Protease inhibitors
ES2235883T3 (en) * 1999-05-06 2005-07-16 Neurogen Corporation 4-OXO-QUINOLINO-3-SUBSTITUTED CARBOXAMIDS: GABA CEREBRAL RECEIVERS LIGANDOS.
WO2001098266A2 (en) * 2000-06-20 2001-12-27 Wayne State University N-and o-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating cns disorders therewith

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344835A (en) * 1990-01-06 1994-09-06 Pfizer Inc. Piperidine and pyrrolidine derivatives
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5300499A (en) * 1992-09-02 1994-04-05 Allergan, Inc. 5-substituted 3-thiophene sulfonamides as antiglaucoma agents
WO1999025686A1 (en) * 1997-11-18 1999-05-27 Teijin Limited Cyclic amine derivatives and their use as drugs

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM. LETT., vol. 9, no. 22, 1999, pages 3211 - 3216 *
DATABASE CAPLUS [online] (COLUMBUS, OHIO, USA); DRESEL ET AL.: "In vivo imaging of serotonin transporters", XP002906926, accession no. STN Database accession no. 1999:196775 *
DATABASE CAPLUS [online] (COLUMBUS, OHIO, USA); DUTTA ET AL.: "Potent and selective ligands for dopamine transporter", XP002906927, accession no. STN Database accession no. 1998:85298 *
DATABASE CAPLUS [online] (COLUMBUS, OHIO, USA); DUTTA ET AL.: "Structural activity relationship studies of novel piperidine analogs", XP002906928, accession no. STN Database accession no. 1996:32788 *
DATABASE CAPLUS [online] (COLUMBUS, OHIO, USA); DUTTA ET AL.: "Tolerance in the replacement of the benzhydrylic on atom", XP002906925, accession no. STN Database accession no. 1998:505470 *
DATABASE CAPLUS [online] (COLUMBUS, OHIO, USA); HOEPPING ET AL.: "Synthesis and biological evaluation of two novel DAT binding technetium complexes", XP002905361, accession no. STN Database accession no. 132:119356 *
EUR. J. NECL. MED., vol. 26, no. 4, 1999, pages 342 - 347 *
J. MED. CHEM., vol. 39, no. 3, 1996, pages 749 - 756 *
J. MED. CHEM., vol. 41, no. 17, 1998, pages 3293 - 3297 *
J. MED. CHEM., vol. 41, no. 5, 1998, pages 699 - 705 *

Also Published As

Publication number Publication date
AU2001275537A1 (en) 2002-01-02
US20100016600A1 (en) 2010-01-21
US6995268B2 (en) 2006-02-07
US20030225133A1 (en) 2003-12-04
US20050154021A1 (en) 2005-07-14
WO2001098266A2 (en) 2001-12-27
US7595331B2 (en) 2009-09-29

Similar Documents

Publication Publication Date Title
WO2001098266A3 (en) N-and o-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating cns disorders therewith
EP0957099A3 (en) Heterocyclic carboxamides
WO2003017927A3 (en) (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
CA2129046A1 (en) Opioid diarylmethylpiperazines and piperidines
MY158859A (en) Pyrrolidine and piperidine derivates as nk1 antagonists
NO20021824L (en) Method of limiting by dynamic production data a fine model representative of the distribution in the reservoir for monophysical quantity characteristic of the subsurface structure
AP9901442A0 (en) 4-(2-Keto-1-benzimidazolinyl) piperidine compounds as orl1-receptor agonists.
AU2002219824A1 (en) Compositions and methods for diagnosing alzheimer's disease
HUP0400236A3 (en) Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride, process for their preparation and pharmaceutical compositions containing them
KR940013508A (en) Compounds for Depression and Parkinson's Syndrome
JP2001019484A5 (en)
WO2009094428A3 (en) N- and o-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating cns disorders therewith
HUP0000141A3 (en) Process for producing the pellets containing at most 90 mass per cent medicative agent
EP1468684A4 (en) Sigma receptor binder containing indanone derivative
JP2002536525A5 (en)
AU2002230665A1 (en) 4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands
EP1096769A3 (en) Methods and systems for building and distributing audio packages
JP2001522888A5 (en)
IS7901A (en) 4- (2-Phenyloxyphenyl) -piperidine or -1,2,3,6-tetrahydropyridine derivatives that inhibit serotonin reuptake
HRP20000502B1 (en) A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-/2-(PIPERIDIN-1-YL)ETHOXY/PHENOXY)-2-(4-METHOXYPHENYL)BENZO/b/THIOPHENE HYDROCHLORIDE
WO2002055491A3 (en) 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a)
ID26146A (en) PROCESS FOR CIS-1- {2- [4- (6-METHOD-2-PHENIL-1,2,3,4-TETRAHYDYRONAFTALEN-1-IL] PHENOCYSI] ETHYL} PYROLIDINE
WO2002055516A3 (en) 1,1-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLOPROTEASE AND TNF-$g(a)
CA2089207A1 (en) Amphoteric Tricyclic Compound
ZA200300218B (en) Novel N-(2-phenyl-3-aminopropyl)naphtamides.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10311796

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP